Medical - Distribution
Compare Stocks
2 / 10Stock Comparison
OMI vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
OMI vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Distribution | Medical - Devices |
| Market Cap | $171M | $113.08B |
| Revenue (TTM) | $2.76B | $25.12B |
| Net Income (TTM) | $-1.10B | $3.25B |
| Gross Margin | — | 63.5% |
| Operating Margin | 1.0% | 22.4% |
| Forward P/E | 2.3x | 19.7x |
| Total Debt | $320M | $14.86B |
| Cash & Equiv. | $282M | $4.01B |
OMI vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | Feb 26 | Return |
|---|---|---|---|
| Owens & Minor, Inc. (OMI) | 100 | 28.2 | -71.8% |
| Stryker Corporation (SYK) | 100 | 188.8 | +88.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OMI vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OMI is the clearest fit if your priority is value.
- Lower P/E (2.3x vs 19.7x)
SYK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 34 yrs, beta 0.55, yield 1.1%
- Rev growth 11.2%, EPS growth 8.2%, 3Y rev CAGR 10.8%
- 191.1% 10Y total return vs OMI's -86.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.2% revenue growth vs OMI's -74.2% | |
| Value | Lower P/E (2.3x vs 19.7x) | |
| Quality / Margins | 12.9% margin vs OMI's -39.8% | |
| Stability / Safety | Beta 0.55 vs OMI's 1.44 | |
| Dividends | 1.1% yield; 34-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | -21.7% vs OMI's -72.6% | |
| Efficiency (ROA) | 6.9% ROA vs OMI's -44.9%, ROIC 11.4% vs 1.8% |
OMI vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
OMI vs SYK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
SYK leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 9.1x OMI's $2.8B. SYK is the more profitable business, keeping 12.9% of every revenue dollar as net income compared to OMI's -39.8%. On growth, SYK holds the edge at +11.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $2.8B | $25.1B |
| EBITDAEarnings before interest/tax | $277M | $6.3B |
| Net IncomeAfter-tax profit | -$1.1B | $3.2B |
| Free Cash FlowCash after capex | -$353M | $4.3B |
| Gross MarginGross profit ÷ Revenue | — | +63.5% |
| Operating MarginEBIT ÷ Revenue | +1.0% | +22.4% |
| Net MarginNet income ÷ Revenue | -39.8% | +12.9% |
| FCF MarginFCF ÷ Revenue | -12.8% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -146.3% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +4.5% | +56.0% |
Valuation Metrics
OMI leads this category, winning 4 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, OMI's 1.7x EV/EBITDA is more attractive than SYK's 20.4x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $171M | $113.1B |
| Enterprise ValueMkt cap + debt − cash | $209M | $123.9B |
| Trailing P/EPrice ÷ TTM EPS | -0.16x | 35.15x |
| Forward P/EPrice ÷ next-FY EPS est. | 2.31x | 19.69x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.36x |
| EV / EBITDAEnterprise value multiple | 1.70x | 20.38x |
| Price / SalesMarket cap ÷ Revenue | 0.06x | 4.50x |
| Price / BookPrice ÷ Book value/share | — | 5.03x |
| Price / FCFMarket cap ÷ FCF | — | 26.40x |
Profitability & Efficiency
SYK leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-21 for OMI. On the Piotroski fundamental quality scale (0–9), SYK scores 6/9 vs OMI's 2/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -21.1% | +15.0% |
| ROA (TTM)Return on assets | -44.9% | +6.9% |
| ROICReturn on invested capital | +1.8% | +11.4% |
| ROCEReturn on capital employed | +1.3% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | — | 0.66x |
| Net DebtTotal debt minus cash | $38M | $10.8B |
| Cash & Equiv.Liquid assets | $282M | $4.0B |
| Total DebtShort + long-term debt | $320M | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | -0.12x | 6.72x |
Total Returns (Dividends Reinvested)
SYK leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SYK five years ago would be worth $12,274 today (with dividends reinvested), compared to $697 for OMI. Over the past 12 months, SYK leads with a -21.7% total return vs OMI's -72.6%. The 3-year compound annual growth rate (CAGR) favors SYK at 2.3% vs OMI's -50.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -3.4% | -14.9% |
| 1-Year ReturnPast 12 months | -72.6% | -21.7% |
| 3-Year ReturnCumulative with dividends | -88.0% | +7.2% |
| 5-Year ReturnCumulative with dividends | -93.0% | +22.7% |
| 10-Year ReturnCumulative with dividends | -86.1% | +191.1% |
| CAGR (3Y)Annualised 3-year return | -50.6% | +2.3% |
Risk & Volatility
SYK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SYK is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than OMI's 1.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SYK currently trades 72.9% from its 52-week high vs OMI's 23.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.44x | 0.55x |
| 52-Week HighHighest price in past year | $9.55 | $404.87 |
| 52-Week LowLowest price in past year | $1.84 | $290.17 |
| % of 52W HighCurrent price vs 52-week peak | +23.5% | +72.9% |
| RSI (14)Momentum oscillator 0–100 | 46.5 | 20.2 |
| Avg Volume (50D)Average daily shares traded | 690K | 2.0M |
Analyst Outlook
SYK leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates OMI as "Hold" and SYK as "Buy". Consensus price targets imply 78.6% upside for OMI (target: $4) vs 36.7% for SYK (target: $404). SYK is the only dividend payer here at 1.14% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $4.00 | $403.69 |
| # AnalystsCovering analysts | 10 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | +1.1% |
| Dividend StreakConsecutive years of raises | 0 | 34 |
| Dividend / ShareAnnual DPS | — | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
SYK leads in 5 of 6 categories (Income & Cash Flow, Profitability & Efficiency). OMI leads in 1 (Valuation Metrics).
OMI vs SYK: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is OMI or SYK a better buy right now?
For growth investors, Stryker Corporation (SYK) is the stronger pick with 11.
2% revenue growth year-over-year, versus -74. 2% for Owens & Minor, Inc. (OMI). Stryker Corporation (SYK) offers the better valuation at 35. 1x trailing P/E (19. 7x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OMI or SYK?
On forward P/E, Owens & Minor, Inc.
is actually cheaper at 2. 3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — OMI or SYK?
Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +22.
7%, compared to -93. 0% for Owens & Minor, Inc. (OMI). Over 10 years, the gap is even starker: SYK returned +191. 1% versus OMI's -86. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OMI or SYK?
By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.
55β versus Owens & Minor, Inc. 's 1. 44β — meaning OMI is approximately 164% more volatile than SYK relative to the S&P 500.
05Which is growing faster — OMI or SYK?
By revenue growth (latest reported year), Stryker Corporation (SYK) is pulling ahead at 11.
2% versus -74. 2% for Owens & Minor, Inc. (OMI). On earnings-per-share growth, the picture is similar: Stryker Corporation grew EPS 8. 2% year-over-year, compared to -201. 1% for Owens & Minor, Inc.. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OMI or SYK?
Stryker Corporation (SYK) is the more profitable company, earning 12.
9% net margin versus -39. 8% for Owens & Minor, Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus 1. 0% for OMI. At the gross margin level — before operating expenses — SYK leads at 64. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OMI or SYK more undervalued right now?
On forward earnings alone, Owens & Minor, Inc.
(OMI) trades at 2. 3x forward P/E versus 19. 7x for Stryker Corporation — 17. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OMI: 78. 6% to $4. 00.
08Which pays a better dividend — OMI or SYK?
In this comparison, SYK (1.
1% yield) pays a dividend. OMI does not pay a meaningful dividend and should not be held primarily for income.
09Is OMI or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +191. 1% 10Y return). Both have compounded well over 10 years (SYK: +191. 1%, OMI: -86. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OMI and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
SYK pays a dividend while OMI does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.